To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

  • STATUS
    Recruiting
  • End date
    Sep 27, 2022
  • participants needed
    200
  • sponsor
    Incyte Corporation
Updated on 4 August 2021
hidradenitis
antiseptics

Summary

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36 -week open-label extension period.

Details
Condition Hidradenitis Suppurativa, Acne Inversa
Treatment Placebo, INCB054707
Clinical Study IdentifierNCT04476043
SponsorIncyte Corporation
Last Modified on4 August 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

HS disease duration of at least 3 months before screening
Willingness to avoid pregnancy or fathering children
Active HS in at least 2 distinct anatomical areas
Participants agree NOT to use topical antiseptics on the areas affected by HS lesions during the placebo-controlled 16-week treatment period

Exclusion Criteria

Draining fistula count of > 20 at screening or baseline
Women who are pregnant (or who are considering pregnancy) or lactating
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
History of failure to treatment of inflammatory diseases with JAK inhibitors
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C
Laboratory values outside of the protocol-defined ranges
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note